aHUS Study LNP023/Novartis. A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy.
Clinical Trial Grant
Administered By
Medicine, Hematology
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
November 30, 2022
End Date
February 28, 2027
Administered By
Medicine, Hematology
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
November 30, 2022
End Date
February 28, 2027